Avalo Therapeutics (NASDAQ: AVTX) — Company Overview, News & Financial Data
Avalo Therapeutics develops innovative treatments for autoimmune and rare diseases through rigorous clinical trials.
Avalo Therapeutics
Avalo Therapeutics (NASDAQ:AVTX) focuses on discovering and developing innovative treatments for patients suffering from complex autoimmune and rare diseases. The company’s operations are mainly concentrated on advancing its pipeline of unique drug candidates through various stages of clinical trials, with the aim to provide new, effective options for conditions with high unmet medical needs. Avalo's projects span a wide range of disorders, including but not limited to, immunology and rare diseases, where the goal is to significantly improve patients' quality of life. Avalo is dedicated to achieving breakthroughs in treatment through rigorous research, clinical development, and strategic collaborations.
Snapshot
Operations
Products and/or services of Avalo Therapeutics
- AVTX-002, an investigational therapy for Crohn’s disease and Ulcerative Colitis.
- AVTX-007, a potential treatment for asthma and allergic diseases by addressing imbalances in the immune system.
- AVTX-006, exploring novel approaches for rare diseases with a focus on genetic disorders.
- Research partnership projects with leading pharmaceutical companies to develop next-generation biologics.
Avalo Therapeutics executive team
- Garry A. NeilPresident, CEO & Director
- Mittie DoyleChief Medical Officer
- Taylor BoydChief Business Officer
- Solomon H. SnyderFounder and Chairman of Scientific Advisory Board
- Barbara S. SlusherFounder and Member of Scientific Advisory Board
- Christopher Ryan SullivanCFO & Head of Investor relations
- Paul C. VarkiChief Legal Officer
- Ashley IvanowiczSenior Vice President of Human Resources
- Dino C. MianoSenior Vice President of CMC & Technical Operations
- Jennifer RileyChief Strategy Officer
Latest news about Avalo Therapeutics
Key financials
Reported results for Avalo Therapeutics, in USD.
- Market cap
- 384.5M
- Revenue (TTM)
- 59K
- P/E ratio
- —
- EPS (diluted, TTM)
- -4.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 59K | -72.9M | -78.3M | |
| 441K | -68.5M | -35.1M | |
| 1.9M | -27.4M | -31.5M | |
| 18.1M | -37.4M | -41.7M |